Post-earnings recap
Reported
Fri, Feb 4, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
Twist Bioscience's earnings report showed a larger-than-expected loss per share, which surprised some investors positively. However, the lack of revenue details and guidance contributed to a negative stock reaction, with shares falling 2.41%. This suggests uncertainty about the company's near-term performance and market conditions.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.91 | N/A | +15.51% |
| Revenue | N/A | N/A | N/A |
Management's tone was defensive, highlighting market challenges without providing specific guidance. They focused on long-term strategies.
Management did not provide specific revenue figures for the quarter.
The company acknowledged ongoing challenges in the market.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—